- Home
- LMFA vs RNAZ Comparison
LMFA vs RNAZ Comparison
Compare LMFA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMFA
- RNAZ
- Stock Information
- Founded
- LMFA 2008
- RNAZ 2016
- Country
- LMFA United States
- RNAZ United States
- Employees
- LMFA N/A
- RNAZ N/A
- Industry
- LMFA Finance: Consumer Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- LMFA Finance
- RNAZ Health Care
- Exchange
- LMFA Nasdaq
- RNAZ Nasdaq
- Market Cap
- LMFA 7.0M
- RNAZ 7.2M
- IPO Year
- LMFA 2015
- RNAZ 2021
- Fundamental
- Price
- LMFA $1.30
- RNAZ $0.53
- Analyst Decision
- LMFA Hold
- RNAZ Strong Buy
- Analyst Count
- LMFA 1
- RNAZ 1
- Target Price
- LMFA N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- LMFA 32.2K
- RNAZ 16.6M
- Earning Date
- LMFA 05-15-2025
- RNAZ 05-14-2025
- Dividend Yield
- LMFA N/A
- RNAZ N/A
- EPS Growth
- LMFA N/A
- RNAZ N/A
- EPS
- LMFA N/A
- RNAZ N/A
- Revenue
- LMFA $10,555,948.00
- RNAZ N/A
- Revenue This Year
- LMFA N/A
- RNAZ $180.81
- Revenue Next Year
- LMFA N/A
- RNAZ N/A
- P/E Ratio
- LMFA N/A
- RNAZ N/A
- Revenue Growth
- LMFA N/A
- RNAZ N/A
- 52 Week Low
- LMFA $1.19
- RNAZ $0.43
- 52 Week High
- LMFA $6.11
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- LMFA 39.86
- RNAZ 28.52
- Support Level
- LMFA $1.19
- RNAZ $0.43
- Resistance Level
- LMFA $1.52
- RNAZ $0.61
- Average True Range (ATR)
- LMFA 0.15
- RNAZ 0.17
- MACD
- LMFA -0.00
- RNAZ 0.21
- Stochastic Oscillator
- LMFA 23.61
- RNAZ 8.24
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.